Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  ImmunoGen, Inc.    IMGN   US45253H1014

IMMUNOGEN, INC. (IMGN)

14
SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
Income Statement Evolution
Annual Income Statement Data
Actuals in M $ Estimates in M $
Fiscal Period June 201220132014201520162017
Sales16,435,559,9101112135
Operating income (EBITDA)--68,4-66,9-54,6-42,3-22,5
Operating profit (EBIT)-73,3-73,0-71,5-58,4-57,8-38,8
Pre-Tax Profit (EBT)-73,3-72,8----
Net income-73,3-72,8-71,4-58,3-59,8-39,9
EPS ( $)-0,95-0,87-0,83-0,68-0,65-0,38
Dividend per Share ( $)------
Yield------
Announcement Date08/03/2012
10:30am
08/02/2013
10:30am
08/01/2014
10:30am
---
Finances - Leverage
Actuals in M $ Estimates in M $
Fiscal Period June 201220132014201520162017
Debt------
Finance-19514280,891,148,3
Operating income (EBITDA)--68,4-66,9-54,6-42,3-22,5
Leverage
(Debt/EBITDA)
------
Capital Expenditure2,903,778,188,026,251,50
Book Value Per Share (BVPS)-1,44 $0,88 $0,37 $0,65 $0,12 $
Cash Flow per Share--0,72 $-0,63 $-0,62 $-0,38 $-
Announcement Date08/03/2012
10:30am
08/02/2013
10:30am
08/01/2014
10:30am
---
Assessed data source :
© 2014 Thomson Reuters
Advertisement
Financial Ratios

Size 2015e 2016e
Capitalization 889 M$ -
Entreprise Value (EV) 809 M$ 798 M$
Valuation 2015e 2016e
PER (Price / EPS)
Capitalization / Revenue 8,84x 7,96x
EV / Revenue 8,04x 7,15x
EV / EBITDA -14,8x -18,9x
Yield (DPS / Price) - -
Profitability 2015e 2016e
Operating Margin (EBIT / Sales) -58,1% -51,8%
operating Leverage (Delta EBIT / Delta Sales) 0,27x 0,09x
Net Margin (Net Profit / Revenue) -57,9% -53,6%
ROA (Net Profit / Asset) - -
ROE (Net Profit / Equities) -115% -101%
Rate of Dividend - -
Balance Sheet Analysis 2015e 2016e
CAPEX / Sales   7,97% 5,60%
Cash Flow / Sales (Taux d'autofinancement) -53,2% -29,0%
Capital Intensity (Assets / Sales) - -
Financial Leverage (Net Debt / EBITDA) 1,48x 2,15x
EPS & Dividend
Dynamic quotes  
ON
| OFF